Source: Benzinga

Cidara: Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Cantor Fitzgerald "Winning Ways to Treat Infections and COVID-19" Virtual Symposium on Tuesday, June 30, 2020.The discussion is intended to provide important updates on how innovative companies, such as Cidara, are leveraging their proprietary technology platforms to develop new ways to treat infections, including COVID diseases. The panelists will also discuss how COVID-19 underscores the need for stockpiling in the U.S. The call will be moderated by Louise Chen, Senior Research Analyst and Managing Director of Cantor Fitzgerald.Presentation Information:Panel: "Winning Ways to Treat Infections and COVID-19"Date: Tuesday, June 30, 2020Time: 11:00 AM ETTo register, please ...Full story available on Benzinga.com

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Jeffrey Stein's photo - President & CEO of Cidara

President & CEO

Jeffrey Stein

CEO Approval Rating

90/100

Cidara develops and commercializes novel anti-infectives and immunotherapies for the treatment of fungal infections. Read more